Gain high value access and increase the profitability of your brands
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MORE"Aligning legislative requirements, payer expectations regarding pricing and evidence, and meeting patients’ needs is now crucial for successful launches.
Learn moreThis is the second in a series of white papers studying the cost of the 340B program. In the first paper, we studied its hidden cost to self-insured employers and their workers. In the current paper, we explore the financial tradeoffs in a 340B revenue sharing agreement: a proposed type of direct contract in which a 340B hospital shares 340B revenue with a self-insured employer.
These findings may help self-insured employers understand the implications of 340B revenue sharing agreements.
Read part 1 here.
Gain high value access and increase the profitability of your brands
Lower contract management costs and mitigate risk.